Investing in Psychedelics for Net Zero Trauma

Investing in Psychedelics for Mental Health

Investors are increasingly turning their attention to psychedelics as a potential game-changer in the field of mental health. The recent $100 million Series A financing for Lykos Therapeutics (formerly known as MAPS Public Benefit Corp.) is a testament to the growing interest in psychedelic therapies. These therapies have the potential to not only manage but cure debilitating mental health conditions such as post-traumatic stress disorder (PTSD). Approximately 13 million adults in the US suffer from PTSD each year, imposing a significant economic burden of at least $232 billion. Lykos Therapeutics’ CEO, Amy Emerson, was motivated to pursue this line of work after witnessing the positive impact of psychedelic therapies on abuse survivors. The company’s new drug application for MDMA (ecstasy) in combination with talk therapy has been submitted to the FDA, and results from Phase 3 clinical trials are promising.